Radius Pharmaceuticals

Part of Radius Health

CompanyUnited States

Radius Pharmaceuticals develops one asset, approved (ELACESTRANT in er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer). Mostly small molecule acting on ESR1; based in the United States.

1
Asset
Furthest stage
Approved
6
Trials
3
Signals

Pipeline

1
  • ELACESTRANT

    Selectively binds estrogen receptor alpha, antagonizing its signaling and promoting its degradation.

    Approved, Small molecule, ESR1, er-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer, Advanced or Metastatic Breast Cancer

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials6
  • Signals3
  • Similar companies6

Intelligence